Skip to main content

A phase II pilot trial of an Indoleamine2,3, dioxygenase-1 (IDO1) Inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma.

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Fred Hutchinson Cancer Research Center

Start Date

September 1, 2013

End Date

August 31, 2014
 

Administered By

Duke Cancer Institute

Awarded By

Fred Hutchinson Cancer Research Center

Start Date

September 1, 2013

End Date

August 31, 2014